Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0456 Transporter Info
Gene Name SLC6A4
Transporter Name Sodium-dependent serotonin transporter
Gene ID
6532
UniProt ID
P31645
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Approved Drug

  Cocaine

            6 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cocaine inhibits the transportation of Mazindol by SLC6A4 [1]

Affected Drug/Substrate

 Mazindol Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  DT Modulation 2

 Cocaine inhibits the transportation of RTI-55 by SLC6A4 [1] , [2]

Affected Drug/Substrate

 RTI-55 Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  DT Modulation 3

 Cocaine inhibits the transportation of Serotonin by SLC6A4 [3]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)1-SERT

  DT Modulation 4

 Cocaine inhibits the transportation of Serotonin by SLC6A4 [4]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  DT Modulation 5

 Cocaine inhibits the activity of SLC6A4 [5] , [6]

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  DT Modulation 6

 Cocaine inhibits the activity of SLC6A4 [3]

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)1-SERT

  Fluoxetine

            5 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fluoxetine inhibits the transportation of Neurotransmitter by SLC6A4 [7]

Affected Drug/Substrate

 Neurotransmitter Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  DT Modulation 2

 Fluoxetine inhibits the transportation of Serotonin by SLC6A4 [8]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)7-SERT

  DT Modulation 3

 Fluoxetine inhibits the transportation of Serotonin by SLC6A4 [4] , [11] , [12]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  DT Modulation 4

 Fluoxetine inhibits the activity of SLC6A4 [16] , [17] , [18]

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  DT Modulation 5

 Fluoxetine modulates the activity of SLC6A4 [19]

  Citalopram

            5 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Citalopram inhibits the transportation of Serotonin by SLC6A4 [8] , [9]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)7-SERT

  DT Modulation 2

 Citalopram inhibits the transportation of Serotonin by SLC6A4 [10]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  DT Modulation 3

 Citalopram inhibits the transportation of RTI-55 by SLC6A4 [13]

Affected Drug/Substrate

 RTI-55 Modulation Type Inhibition

  DT Modulation 4

 Citalopram inhibits the activity of SLC6A4 [14] , [15]

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  DT Modulation 5

 Citalopram modulates the activity of SLC6A4 [19]

  Reboxetine

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Reboxetine inhibits the transportation of Citalopram by SLC6A4 [20] , [21]

Affected Drug/Substrate

 Citalopram Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  DT Modulation 2

 Reboxetine inhibits the transportation of RTI-55 by SLC6A4 [13]

Affected Drug/Substrate

 RTI-55 Modulation Type Inhibition

  DT Modulation 3

 Reboxetine inhibits the activity of SLC6A4 [29]

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  Duloxetine

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Duloxetine inhibits the transportation of Citalopram by SLC6A4 [21]

Affected Drug/Substrate

 Citalopram Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  DT Modulation 2

 Duloxetine inhibits the transportation of Paroxetine by SLC6A4 [25]

Affected Drug/Substrate

 Paroxetine Modulation Type Inhibition

  DT Modulation 3

 Duloxetine inhibits the activity of SLC6A4 [26] , [27] , [28]

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  Mazindol

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Mazindol inhibits the transportation of Mazindol by SLC6A4 [1]

Affected Drug/Substrate

 Mazindol Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  DT Modulation 2

 Mazindol inhibits the transportation of RTI-55 by SLC6A4 [1]

Affected Drug/Substrate

 RTI-55 Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  DT Modulation 3

 Mazindol inhibits the activity of SLC6A4 [5]

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  Venlafaxine

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Venlafaxine inhibits the transportation of Neurotransmitter by SLC6A4 [7]

Affected Drug/Substrate

 Neurotransmitter Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  DT Modulation 2

 Venlafaxine inhibits the transportation of Serotonin by SLC6A4 [4] , [12]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  DT Modulation 3

 Venlafaxine inhibits the activity of SLC6A4 [28]

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  Escitalopram

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Escitalopram inhibits the transportation of Serotonin by SLC6A4 [22]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)7-SERT

  DT Modulation 2

 Escitalopram inhibits the transportation of Serotonin by SLC6A4 [23]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  DT Modulation 3

 Escitalopram inhibits the activity of SLC6A4 [30]

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  Imipramine

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Imipramine inhibits the transportation of Serotonin by SLC6A4 [24]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  DT Modulation 2

 Imipramine inhibits the activity of SLC6A4 [31] , [32]

Cell System

 Chinese hamster ovary (CHO) cells-SERT

  DT Modulation 3

 Imipramine inhibits the activity of SLC6A4 [33]

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  Amitriptyline

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Amitriptyline inhibits the transportation of Serotonin by SLC6A4 [4]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  DT Modulation 2

 Amitriptyline inhibits the activity of SLC6A4 [36] , [37] , [38]

  Ziprasidone

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ziprasidone inhibits the activity of SLC6A4 [34]

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  DT Modulation 2

 Ziprasidone inhibits the activity of SLC6A4 [35]

Cell System

 Chinese hamster ovary (CHO) cells-SERT

  Paroxetine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Paroxetine inhibits the activity of SLC6A4 [14] , [15] , [33]

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  DT Modulation 2

 Paroxetine modulates the activity of SLC6A4 [19]

  Desvenlafaxine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Desvenlafaxine inhibits the activity of SLC6A4 [28]

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  DT Modulation 2

 Desvenlafaxine modulates the activity of SLC6A4 [41]

  Fluvoxamine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fluvoxamine inhibits the activity of SLC6A4 [39] , [40]

  DT Modulation 2

 Fluvoxamine modulates the activity of SLC6A4 [43]

  Vilazodone

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Vilazodone modulates the activity of SLC6A4 [42]

  DT Modulation 2

 Vilazodone inhibits the activity of SLC6A4 [44]

  4-Fluoroamphetamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 4-Fluoroamphetamine inhibits the transportation of Dopamine by SLC6A4 (IC50 = 19 microM) [45]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  4-Fluoromethamphetamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 4-Fluoromethamphetamine inhibits the transportation of Dopamine by SLC6A4 (IC50 = 8.7 microM) [45]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  Amphetamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Amphetamine inhibits the transportation of Dopamine by SLC6A4 (IC50 = 45 microM) [45]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  Ephedrine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ephedrine inhibits the transportation of Dopamine by SLC6A4 (IC50 = 230 microM) [45]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  Methamphetamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methamphetamine inhibits the transportation of Dopamine by SLC6A4 (IC50 = 18 microM) [45]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  Dextroamphetamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dextroamphetamine inhibits the transportation of Serotonin by SLC6A4 [4]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  Modafinil

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Modafinil inhibits the transportation of Serotonin by SLC6A4 [46]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)7-SERT

  Dopamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dopamine inhibits the activity of SLC6A4 [47]

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  Methylphenidate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methylphenidate inhibits the activity of SLC6A4 [48]

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  Aripiprazole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Aripiprazole inhibits the activity of SLC6A4 [34]

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  Chlorpromazine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Chlorpromazine inhibits the activity of SLC6A4 [34]

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  Bupropion

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bupropion inhibits the activity of SLC6A4 [6]

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  Moclobemide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Moclobemide inhibits the activity of SLC6A4 [35]

Cell System

 Chinese hamster ovary (CHO) cells-SERT

  Pimozide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pimozide inhibits the activity of SLC6A4 [35]

Cell System

 Chinese hamster ovary (CHO) cells-SERT

  Risperidone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Risperidone inhibits the activity of SLC6A4 [35]

Cell System

 Chinese hamster ovary (CHO) cells-SERT

  Clomipramine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Clomipramine inhibits the activity of SLC6A4 [49]

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  Simvastatin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Simvastatin increases the activity of SLC6A4 [50]

  Lamivudine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Lamivudine increases the expression of SLC6A4 [51]

  Ribavirin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ribavirin increases the expression of SLC6A4 [51]

  Copper Sulfate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Copper Sulfate inhibits the expression of SLC6A4 [52]

  Hydrogen Peroxide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Hydrogen Peroxide affects the expression of SLC6A4 [53]

  Cyclosporine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cyclosporine inhibits the expression of SLC6A4 [54]

  Urethane

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Urethane inhibits the expression of SLC6A4 [55]

  Estradiol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Estradiol inhibits the expression of SLC6A4 [56]

  Gabapentin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Gabapentin inhibits the expression of SLC6A4 [56]

  Hydroxyurea

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Hydroxyurea inhibits the expression of SLC6A4 [56]

  Sulfadiazine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sulfadiazine inhibits the expression of SLC6A4 [56]

  Valproic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Valproic Acid inhibits the expression of SLC6A4 [56]

  Amfepramone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Amfepramone inhibits the activity of SLC6A4 [57] , [58]

  Sertraline

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sertraline inhibits the activity of SLC6A4 [59] , [60]

  Vortioxetine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Vortioxetine inhibits the activity of SLC6A4 [61] , [62] , [63]

  Dextromethorphan polistirex

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dextromethorphan polistirex modulates the activity of SLC6A4 [19]

  Nortriptyline

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Nortriptyline modulates the activity of SLC6A4 [19]

  Sibutramine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sibutramine modulates the activity of SLC6A4 [19]

  Trazodone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Trazodone modulates the activity of SLC6A4 [19]

  Chlorphentermine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Chlorphentermine modulates the activity of SLC6A4 [64]

  Acetaminophen

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Acetaminophen inhibits the activity of SLC6A4 [65]

  Tianeptine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tianeptine inhibits the activity of SLC6A4 [66]

  Levomilnacipran

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Levomilnacipran modulates the activity of SLC6A4 [67]

  Clozapine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Clozapine inhibits the activity of SLC6A4 [68]

  Olanzapine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Olanzapine inhibits the activity of SLC6A4 [68]

  Quetiapine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Quetiapine inhibits the activity of SLC6A4 [68]

  Haloperidol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Haloperidol inhibits the activity of SLC6A4 [68] , [69]

  Scopolamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Scopolamine induces the activity of SLC6A4 [70]

Drug in Phase 3 Trial

  Pridopidine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pridopidine inhibits the activity of SLC6A4 [35]

Cell System

 Chinese hamster ovary (CHO) cells-SERT

  Triclosan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Triclosan inhibits the expression of SLC6A4 [77]

  Dasotraline

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dasotraline inhibits the activity of SLC6A4 [82]

  Litoxetine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Litoxetine modulates the activity of SLC6A4 [83]

  Bicifadine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bicifadine modulates the activity of SLC6A4 [84]

  Amitifadine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Amitifadine inhibits the activity of SLC6A4 [85] , [86] , [87]

Drug in Phase 2 Trial

  Bisphenol A

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bisphenol A inhibits the expression of SLC6A4 [56]

Drug in Phase 1 Trial

  CCRIS-9277

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 CCRIS-9277 inhibits the expression of SLC6A4 [71]

  Quercetin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Quercetin inhibits the expression of SLC6A4 [72]

Investigative Drug

  3',4'-Methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP)

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 3',4'-Methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP) inhibits the transportation of Dopamine by SLC6A4 (IC50 = 15 microM) [45]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  3',4'-Methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP)

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 3',4'-Methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP) inhibits the transportation of Dopamine by SLC6A4 (IC50 = 75 microM) [45]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  Methcathinone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methcathinone inhibits the transportation of Dopamine by SLC6A4 (IC50 = 46 microM) [45]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  Methylenedioxypyrovalerone (MDPV)

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methylenedioxypyrovalerone (MDPV) inhibits the transportation of Dopamine by SLC6A4 (IC50 = 9.6 microM) [45]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  Pyrovalerone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pyrovalerone inhibits the transportation of Dopamine by SLC6A4 (IC50 = 23 microM) [45]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  Serotonin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Serotonin increases the activity of SLC6A4 [81]

Patented Pharmaceutical Agent

  GSK-J4

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 GSK-J4 increases the expression of SLC6A4 [76]

Drug Withdrawn

  Naphyrone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Naphyrone inhibits the transportation of Dopamine by SLC6A4 (IC50 = 0.8 microM) [45]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

Natural Product

  4-Fluoroephedrine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 4-Fluoroephedrine inhibits the transportation of Dopamine by SLC6A4 (IC50 = 134 microM) [45]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SERT

  Particulate Matter

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Particulate Matter inhibits the expression of SLC6A4 [74]

  Methyleugenol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methyleugenol inhibits the expression of SLC6A4 [78]

  Tobacco Smoke Pollution

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tobacco Smoke Pollution increases the expression of SLC6A4 [80]

Environmental toxicant

  Glyphosate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Glyphosate inhibits the expression of SLC6A4 [56]

Mycotoxins

  Aflatoxin B1

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Aflatoxin B1 inhibits the expression of SLC6A4 [56]

  Fumonisin B1

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fumonisin B1 inhibits the expression of SLC6A4 [56]

Acute Toxic Substance

  Formaldehyde

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Formaldehyde inhibits the expression of SLC6A4 [75]

  Ochratoxin A

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ochratoxin A inhibits the expression of SLC6A4 [56]

Carcinogen

  Benzo(a)pyrene

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Benzo(a)pyrene inhibits the expression of SLC6A4 [78]

Health and Environmental Toxicant

  tris(1,3-dichloro-2-propyl)phosphate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC6A4 [73]

  Perfluorooctane sulfonic acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Perfluorooctane sulfonic acid inhibits the expression of SLC6A4 [79]

  Lithium Chloride

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Lithium Chloride inhibits the expression of SLC6A4 [56]
References
1 Scaffold Repurposing of Nucleosides (Adenosine Receptor Agonists): Enhanced Activity at the Human Dopamine and Norepinephrine Sodium Symporters. J Med Chem. 2017 Apr 13;60(7):3109-3123.
2 Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors. J Med Chem. 1999 Sep 9;42(18):3647-56.
3 Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters. Bioorg Med Chem. 2007 Jun 15;15(12):4159-74.
4 An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3411-5.
5 Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter. J Med Chem. 2002 Sep 12;45(19):4097-109.
6 Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
7 Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3--Oxyazetidine. ACS Med Chem Lett. 2014 Jul 10;5(9):999-1004.
8 From the selective serotonin transporter inhibitor citalopram to the selective norepinephrine transporter inhibitor talopram: synthesis and structure-activity relationship studies. J Med Chem. 2008 May 22;51(10):3045-8.
9 A rhodamine-labeled citalopram analogue as a high-affinity fluorescent probe for the serotonin transporter. Bioorg Med Chem Lett. 2013 Jan 1;23(1):323-6.
10 Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents. Bioorg Med Chem. 2011 Feb 1;19(3):1328-48.
11 Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors. Bioorg Med Chem Lett. 2013 Oct 15;23(20):5515-8.
12 Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors. Bioorg Med Chem Lett. 2014 Aug 1;24(15):3234-7.
13 Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter. J Med Chem. 2004 Feb 26;47(5):1122-35.
14 Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter. Bioorg Med Chem. 2008 Jun 15;16(12):6364-70.
15 3-(4-(6-Fluoroalkoxy-3,4-dihydroisoquinoline-2(1H)-yl)cyclohexyl)-1H-indole-5-carbonitriles for SERT imaging: chemical synthesis, evaluation in vitro and radiofluorination. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4727-30.
16 Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43.
17 Dual inhibitors of phosphodiesterase-4 and serotonin reuptake. J Med Chem. 2009 Mar 26;52(6):1530-9.
18 Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells. Bioorg Med Chem Lett. 2013 Mar 15;23(6):1834-8.
19 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
20 [4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1795-8.
21 Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition. Bioorg Med Chem Lett. 2008 Apr 15;18(8):2562-6.
22 Novel and high affinity fluorescent ligands for the serotonin transporter based on (s)-citalopram. ACS Med Chem Lett. 2014 Mar 27;5(6):696-9.
23 Novel Azido-Iodo Photoaffinity Ligands for the Human Serotonin Transporter Based on the Selective Serotonin Reuptake Inhibitor (S)-Citalopram. J Med Chem. 2015 Jul 23;58(14):5609-19.
24 Synthesis and inhibitory evaluation of 3-linked imipramines for the exploration of the S2 site of the human serotonin transporter. Bioorg Med Chem. 2016 Jun 15;24(12):2725-38.
25 Synthesis and biological activity of some known and putative duloxetine metabolites. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3481-6.
26 Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
27 N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5078-81.
28 Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor. ACS Med Chem Lett. 2013 May 7;4(6):560-4.
29 Synthesis, radiosynthesis, and biological evaluation of carbon-11 and fluorine-18 labeled reboxetine analogues: potential positron emission tomography radioligands for in vivo imaging of the norepinephrine transporter. J Med Chem. 2009 Jan 8;52(1):62-73.
30 Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5552-5.
31 Novel arylsulfonamide derivatives with 5-HT6/5-HT7 receptor antagonism targeting behavioral and psychological symptoms of dementia. J Med Chem. 2014 Jun 12;57(11):4543-57.
32 Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia. Eur J Med Chem. 2015 Mar 6;92:221-35.
33 Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT 1A weak partial agonistic activity showing the antidepressant-like effect. Bioorg Med Chem. 2017 Jan 1;25(1):293-304.
34 Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. J Med Chem. 2007 Oct 18;50(21):5103-8.
35 Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach. J Med Chem. 2012 Nov 26;55(22):9735-50.
36 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
37 A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):285-90.
38 The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds. Bioorg Med Chem Lett. 2014 Jan 15;24(2):576-9.
39 Changes of functional MRI findings in a patient whose pathological gambling improved with fluvoxamine. Yonsei Med J. 2009 Jun 30;50(3):441-4.
40 Placebo controlled double-blind trial of fluvoxamine maleate in the obese. J Psychosom Res. 1986;30(2):143-6.
41 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
42 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
43 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
44 Benzothiazoles as probes for the 5HT1A receptor and the serotonin transporter (SERT): a search for new dual-acting agents as potential antidepressants. Eur J Med Chem. 2012 Jul;53:124-32.
45 Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones. Eur Neuropsychopharmacol. 2015 Mar;25(3):365-76.
46 Elucidation of structural elements for selectivity across monoamine transporters: novel 2-[(diphenylmethyl)sulfinyl]acetamide (modafinil) analogues. J Med Chem. 2014 Feb 13;57(3):1000-13.
47 Synthesis and biological activity of 2-carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes. Bioorg Med Chem Lett. 2003 Nov 17;13(22):4133-7.
48 Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem. 2007 Jan 25;50(2):219-32.
49 Reengineered tricyclic anti-cancer agents. Bioorg Med Chem. 2015 Oct 1;23(19):6528-34.
50 Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Res. 2005 Feb 28;133(2-3):197-203.
51 Serotonin transporter mRNA expression is decreased by lamivudine and ribavirin and increased by interferon in immune cells. Scand J Immunol. 2006 Feb;63(2):106-15.
52 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
53 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203.
54 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
55 Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
56 Establishment of a 13 genes-based molecular prediction score model to discriminate the neurotoxic potential of food relevant-chemicals. Toxicol Lett. 2022 Feb 1;355:1-18.
57 Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
58 Phentermine and anaesthesia. Anaesth Intensive Care. 2005 Aug;33(4):525-7.
59 Methadone: from pharmacokinetic profile to clinical pharmacology. Encephale. 2006 Jul-Aug;32(4 Pt 1):478-86.
60 Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
61 A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012 Jun;15(5):589-600.
62 Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav. 2013 Apr;105:41-50.
63 2013 FDA drug approvals. Nat Rev Drug Discov. 2014 Feb;13(2):85-9.
64 Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates.Implications for primary pulmonary hypertension.Circulation.1999 Aug 24;100(8):869-75.
65 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Jun 11.
66 Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39.
67 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
68 Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. Bioorg Med Chem. 2008 Aug 1;16(15):7291-301.
69 Further evaluation of the tropane analogs of haloperidol. Bioorg Med Chem Lett. 2014 Sep 1;24(17):4294-7.
70 BDNF mediates the protective effects of scopolamine in reserpine-induced depression-like behaviors via up-regulation of 5-HTT and TPH1. Psychiatry Res. 2019 Jan;271:328-334.
71 Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance. Psychopharmacology (Berl). 2008 Oct;200(3):439-50.
72 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
73 Defensive and adverse energy-related molecular responses precede tris (1, 3-dichloro-2-propyl) phosphate cytotoxicity. J Appl Toxicol. 2016 May;36(5):649-58.
74 Redox/methylation mediated abnormal DNA methylation as regulators of ambient fine particulate matter-induced neurodevelopment related impairment in human neuronal cells. Sci Rep. 2016 Sep 14;6:33402.
75 Cellular reactions to long-term volatile organic compound (VOC) exposures. Sci Rep. 2016 Dec 1;6:37842.
76 Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells. J Biol Chem. 2018 Feb 16;293(7):2422-2437.
77 Transcriptome and DNA Methylome Dynamics during Triclosan-Induced Cardiomyocyte Differentiation Toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
78 Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297.
79 An assessment of serum-dependent impacts on intracellular accumulation and genomic response of per- and polyfluoroalkyl substances in a placental trophoblast model. Environ Toxicol. 2020 Dec;35(12):1395-1405.
80 Integration of transcriptome analysis with pathophysiological endpoints to evaluate cigarette smoke toxicity in an in vitro human airway tissue model. Arch Toxicol. 2021 May;95(5):1739-1761.
81 Functional characterization of N-octyl 4-methylamphetamine variants and related bivalent compounds at the dopamine and serotonin transporters using Ca2+ channels as sensors. Toxicol Appl Pharmacol. 2021 May 15;419:115513.
82 Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
83 Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur J Pharmacol. 1993 Mar 2;232(2-3):139-45.
84 Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine
85 Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 928).
86 1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors. J Med Chem. 2010 Mar 25;53(6):2534-51.
87 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J Med Chem. 2010 Jul 8;53(13):4989-5001.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.